Many factors must be considered and discussed with women when initiating a contraceptive
method and the risk of venous thromboembolism (VTE) is one of them. In this review, we …

The use of oral contraceptives (OC) is a well established risk factor for venous thrombosis. It
has been known for many years that almost all haemostatic parameters ie plasma levels of …

The incidence of venous thrombosis associated with estrogen treatment in male-to-female
(M→ F) transsexuals is considerably higher with administration of oral ethinyl estradiol (EE) …

The use of oral contraceptives (OC) causes disturbances of the procoagulant, anticoagulant
and fibrinolytic pathways of blood coagulation which may contribute to the increased risk of …

Thrombosis is a deadly malfunctioning of the hemostatic system occurring in numerous
conditions and states, from surgery and pregnancy to cancer, sepsis and infarction. Despite …

We used the thrombin generation assay to evaluate the hypercoagulable state according to
JAK2 V617F mutational status in essential thrombocythemia (ET) and polycythemia vera …

Objective—Activated protein C (APC) resistance not related to the factor V Leiden mutation
is a risk factor for venous thrombosis. Oral estrogen replacement therapy (ERT) has been …

Proteolytic inactivation of factors Va (FVa) and VIIIa (FVIIIa) by activated protein C (APC) and
its cofactors protein S and factor V (FV) is a key process in the physiological down …

Rivaroxaban (BAY 59‐7939) is an oral, direct factor Xa inhibitor in advanced development.
This study was undertaken to investigate its effects on thrombin generation. In this placebo …

Objective—The purpose of this study was to investigate whether the effect of transdermal
estrogen therapy in postmenopausal women differs from that of oral therapy with regard to …